CJC-1295 and Ipamorelin: How Growth Hormone Secretagogue Peptides Work and What the Research Shows

CJC-1295 and Ipamorelin are two of the most frequently discussed growth hormone secretagogue (GHS) peptides in both clinical and grey-market contexts. Understanding what the published research actually shows, and where the evidence gaps remain, is important for researchers and clinicians evaluating these compounds. The Peptide Register catalogues both peptides in its peptide database with structured profiles covering mechanism, evidence quality, and regulatory status.

This post reviews the pharmacology, published data, and regulatory landscape for each peptide. For foundational context on what peptides are and how they differ from other molecules, see our overview on how peptides differ from proteins, hormones, and small molecules.

Mechanism of Action: How CJC-1295 and Ipamorelin Stimulate Growth Hormone Release

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), the endogenous hypothalamic peptide that signals the anterior pituitary to release growth hormone (GH). CJC-1295 is a synthetic GHRH analogue consisting of 29 amino acids with chemical modifications designed to resist enzymatic degradation. The most studied form, CJC-1295 with Drug Affinity Complex (DAC), binds to serum albumin, which extends its plasma half-life significantly compared to native GHRH.

Ipamorelin is a synthetic pentapeptide that acts as a selective growth hormone secretagogue receptor (GHS-R) agonist. Ipamorelin is a selective GHS receptor agonist that stimulates growth hormone release without significantly elevating cortisol or prolactin in published studies. This selectivity distinguishes it from earlier GHS-R agonists such as GHRP-6 and GHRP-2, which showed broader hormonal effects in preclinical work.

When discussed together, CJC-1295 and Ipamorelin represent two distinct mechanisms: GHRH receptor activation and GHS receptor activation. Some researchers have hypothesised that combining GHRH-pathway and ghrelin-pathway stimulation may produce synergistic GH release, though robust clinical trial data on this specific combination remains limited.

Published Clinical and Preclinical Evidence

CJC-1295 with DAC was studied in a 2006 clinical trial published in the Journal of Clinical Endocrinology and Metabolism. CJC-1295 with DAC increased mean plasma GH levels by two to tenfold for six or more days following a single subcutaneous injection in a published 2006 clinical study. The same study reported sustained elevations in IGF-1 (insulin-like growth factor 1) over a comparable period. However, the trial enrolled only healthy adult subjects in relatively small cohorts, and longer-term safety and efficacy data from randomised controlled trials remain sparse.

Ipamorelin has been evaluated in both animal models and small human studies. In a 1998 study in healthy male volunteers, Ipamorelin produced dose-dependent GH release in healthy male volunteers in early clinical studies without significant increases in ACTH or cortisol. Animal studies have explored its potential effects on bone mineral content and body composition, but these findings have not been replicated in large human trials.

It is important to note that neither CJC-1295 nor Ipamorelin has completed the full regulatory approval process for any therapeutic indication in any major jurisdiction. The evidence base consists primarily of early-phase studies with small sample sizes and limited follow-up. For guidance on evaluating such studies, the Peptide Register provides a resource on how to read peptide research.

Evidence Limitations and Safety Considerations

Neither CJC-1295 nor Ipamorelin has been approved by the FDA or TGA for any therapeutic indication as of 2025. The absence of Phase III clinical trial data means that long-term safety profiles for both peptides remain poorly characterised.

Reported side effects in early studies included injection site reactions, water retention, and transient flushing. CJC-1295 with DAC was associated with at least one reported death during a clinical trial programme, though the causal relationship was not definitively established. This event contributed to a pause in further clinical development of the DAC formulation.

Sustained GH and IGF-1 elevation carries theoretical risks including insulin resistance, joint pain, and potential effects on cell proliferation, though these concerns are extrapolated largely from exogenous GH therapy data rather than from secretagogue-specific studies. Long-term safety data for CJC-1295 and Ipamorelin in humans remain insufficient to draw definitive conclusions about risk profiles.

Regulatory Status Across Jurisdictions

In the United States, CJC-1295 and Ipamorelin are not FDA-approved drugs. CJC-1295 appeared on the FDA's Category 1 bulk drug substances list, which affects its availability through compounding pharmacies. For more on how that list impacts access, see our analysis of the FDA Category 1 list and its impact on compounding.

In Australia, both peptides are classified as Schedule 4 (prescription-only) substances under TGA scheduling. They may only be legally accessed through a prescribing practitioner. In Australia, CJC-1295 and Ipamorelin are classified as Schedule 4 prescription-only medicines under TGA regulations. The Peptide Register's provider directory lists licensed practitioners in relevant jurisdictions for those seeking clinical guidance.

In the European Union and United Kingdom, neither peptide has marketing authorisation, and their legal status varies by member state. Researchers and clinicians should consult jurisdiction-specific regulations before considering any investigational use.

Summary

CJC-1295 and Ipamorelin operate through complementary but distinct pathways to stimulate pituitary growth hormone release. Early-phase clinical data suggest both peptides can elevate GH and IGF-1 levels, but the evidence base remains limited to small, short-duration studies. No large randomised controlled trials have established therapeutic efficacy or long-term safety for either peptide. Regulatory frameworks in the US, Australia, and Europe reflect this evidence gap, with neither peptide approved for any clinical indication. The Peptide Register provides structured profiles and ongoing regulatory monitoring for both compounds as part of its independent peptide reference platform.